查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1525988

分子診斷市場：2024-2031 年全球產業分析、規模、份額、成長、趨勢、預測

Molecular Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024 - 2031
出版日期: | 出版商: Persistence Market Research | 英文 225 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

Persistence Market Research最近發佈了一份關於全球分子診斷市場的綜合報告。該報告對關鍵市場動態進行了深入分析，包括市場驅動因素、趨勢、機會和課題，並對市場結構提供了深入的見解。

重要見解

  • 分子診斷市場規模（2024年）：232億美元
  • 預測市場規模（2031年）：356億美元
  • 全球市場成長率（2024-2031年複合年增長率）：6.2%

分子診斷市場-研究範圍：

分子診斷分析基因組和蛋白質組中的生物標記以診斷和監測疾病。該市場包括聚合□鏈反應（PCR）、下一代定序（NGS）和原位雜交等技術。分子診斷對於遺傳疾病、傳染病和某些癌症的診斷至關重要，並且透過深入瞭解患者獨特的疾病特徵，在個人化醫療中發揮重要作用。

市場成長動力：

全球分子診斷市場由幾個關鍵因素推動，包括遺傳性疾病和傳染病的日益流行，以及對個人化醫療不斷增長的需求。分子診斷技術的進步，例如高通量測序和先進生物資訊工具的開發，正在提高診斷的準確性和效率。醫療保健支出的增加和對預防醫學的日益關注進一步促進了市場的成長。此外，分子診斷在新興市場的擴張以及分子測試在腫瘤學中的日益普及正在為市場擴張創造新的機會。

市場限制因素：

儘管成長前景廣闊，但分子診斷市場面臨高成本和複雜監管要求的課題。先進診斷設備和測試的高昂成本可能會限制資源匱乏地區和新興國家的取得。此外，分子診斷測試的批准和報銷的嚴格監管流程可能會阻礙市場進入並減緩創新。持續投資研發的需要以及遵守監管標準的需要是市場成長的主要障礙。

市場機會：

由於技術進步、人口趨勢和不斷變化的醫療保健需求，分子診斷市場提供了巨大的商機。分子診斷技術的創新，例如便攜式診斷設備的開發以及診斷中人工智慧（AI）的集成，正在為市場成長開闢新的途徑。分子診斷在癌症、傳染病、遺傳疾病等各個治療領域的日益增長的應用正在擴大市場範圍。策略合作夥伴關係、研發投資以及引入具有成本效益的診斷解決方案對於利用新的商機和保持市場領先地位至關重要。

本報告解決的關鍵問題

  • 推動分子診斷市場全球成長的關鍵因素是什麼？
  • 哪些診斷技術和應用正在推動分子診斷在各種醫療保健環境中的採用？
  • 技術進步如何改變分子診斷市場的競爭格局？
  • 誰是分子診斷市場的主要參與者？
  • 全球分子診斷市場有哪些新趨勢與未來前景？

目錄

第1章 內容提要

第2章 市場概況

  • 市場範圍和定義
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會
    • 任務
    • 主要趨勢
  • 分子診斷市場：價值鏈
    • 製造商名單
    • 經銷商名單
    • 獲利能力分析
  • 宏觀經濟因素
    • 世界產業展望
    • 世界GDP成長展望
    • 全球母公司市場概覽
  • 預測變量 - 相關性和影響
  • COVID-19 影響評估
  • 技術進步
  • 疾病流行病學
  • 波特五力分析
  • 監管場景
  • 產品採用分析
  • 母市場分析

第三章 2024-2031年價格趨勢分析

  • 主要亮點
  • 影響產品價格的主要因素
  • 按產品類型劃分的價格
  • 區域定價和產品偏好

第四章全球分子診斷市場展望：過去（2019-2023）與預測（2024-2031）

  • 主要亮點
    • 按產品類型預測的市場規模（單位）
    • 市場規模及年成長率
    • 絕對的$機會
  • 市場規模分析與預測
    • 過去的市場規模分析，2019-2023
    • 目前市場規模預測，2024-2031
  • 全球分子診斷市場展望：產品類型
    • 簡介/主要發現
    • 2019年至2023年按產品類型劃分的市場規模與數量（單位）分析
    • 目前市場規模和產品類型數量（單位）預測，2024-2031
      • 機器
        • 聚合□連鎖反應（PCR）系統
        • 雜交（原位雜交和FISH）系統
        • DNA定序與下一代定序平台
        • 微陣列
      • 試劑
        • 抗體
        • 脫氧核糖核酸模板
        • DNA聚合□
        • 寡核甘酸引子
        • 脫氧核糖核甘酸三磷酸 (dNTP)
        • 緩衝
      • 檢測試劑盒
      • 消耗品
  • 市場吸引力分析：產品類型
  • 全球分子診斷市場展望：疾病領域
    • 簡介/主要發現
    • 2019年至2023年按疾病領域劃分的市場規模歷史分析
    • 2024-2031 年按疾病領域劃分的當前市場規模預測
      • 感染
      • 糖尿病
      • 心臟病學
      • 腫瘤學
      • 腎臟科
      • 自身免疫性疾病
      • 皮膚科
      • 傷口護理
      • 其他
  • 市場吸引力分析：疾病領域
  • 全球分子診斷市場展望：最終用戶
    • 簡介/主要發現
    • 2019-2023 年最終用戶市場規模歷史分析
    • 2024-2031 年最終用戶當前市場規模預測
      • 醫院/診所
      • 診斷實驗室
      • 學術研究所
      • 生物製藥公司
  • 市場吸引力分析：最終用戶

第五章全球分子診斷市場展望：地區

  • 主要亮點
  • 2019-2023年按地區市場規模歷史分析
  • 2024-2031 年各地區目前市場規模預測
    • 北美
    • 歐洲
    • 東亞
    • 南亞和大洋洲
    • 拉丁美洲
    • 中東/非洲
  • 市場吸引力分析：區域

第六章北美分子診斷市場展望：過去（2019-2023）與預測（2024-2031）

第七章歐洲分子診斷市場展望：過去（2019-2023）與預測（2024-2031）

第八章東亞分子診斷市場展望：過去（2019-2023）與預測（2024-2031）

第9章南亞和大洋洲分子診斷市場展望：歷史（2019-2023）和預測（2024-2031）

第10章拉丁美洲分子診斷市場展望：過去（2019-2023）與預測（2024-2031）

第十一章中東與非洲分子診斷市場展望：過去（2019-2023）與預測（2024-2031）

第12章 競爭格局

  • 2024 年市場份額分析
  • 市場結構
    • 按市場劃分的競爭加劇地圖
    • 比賽儀表板
  • 公司簡介（詳細資訊 - 概述、財務、策略、近期發展）
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories Inc
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Agilent Technologies, Inc.
    • Hoffmann la roche
    • Qiagen NV
    • Illumina, Inc.
    • DiaSorin SpA
    • Hologic Inc.
    • Siemens Healthineers AG
    • Seegene, Inc.
    • Grifols, SA
    • bioMerieux
    • QuidelOrtho Corporation
    • RapidBio
    • Abbott Laboratories
    • Danaher Corporation

第13章 附錄

  • 調查方法
  • 調查假設
  • 縮寫
簡介目錄
Product Code: PMRREP2784

Persistence Market Research has recently released a comprehensive report on the global molecular diagnostics market. This report provides an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges, and offers detailed insights into the market structure.

Key Insights:

  • Molecular Diagnostics Market Size (2024E): USD 23.2 Bn
  • Projected Market Value (2031F): USD 35.6 Bn
  • Global Market Growth Rate (CAGR 2024 to 2031):6.2%

Molecular Diagnostics Market - Report Scope:

Molecular diagnostics involve the analysis of biological markers in the genome and proteome to diagnose and monitor diseases. This market includes technologies like polymerase chain reaction (PCR), next-generation sequencing (NGS), and in situ hybridization. Molecular diagnostics are essential for diagnosing genetic disorders, infectious diseases, and certain cancers, and play a crucial role in personalized medicine by providing insights into patient-specific disease profiles.

Market Growth Drivers:

The global molecular diagnostics market is driven by several key factors, including the increasing prevalence of genetic disorders and infectious diseases, and the growing demand for personalized medicine. Advancements in molecular diagnostic technologies, such as the development of high-throughput sequencing and advanced bioinformatics tools, are enhancing diagnostic accuracy and efficiency. The rise in healthcare expenditures and the increasing focus on preventive healthcare further contribute to market growth. Additionally, the expansion of molecular diagnostics in emerging markets and the growing adoption of molecular tests in oncology are creating new opportunities for market expansion.

Market Restraints:

Despite promising growth prospects, the molecular diagnostics market faces challenges related to high costs and complex regulatory requirements. The high price of advanced diagnostic equipment and tests can limit access in low-resource settings and emerging economies. Additionally, the stringent regulatory processes for approval and reimbursement of molecular diagnostic tests can impede market entry and slow down innovation. The need for continuous investment in R&D and the necessity to comply with regulatory standards pose significant barriers to market growth.

Market Opportunities:

The molecular diagnostics market presents significant opportunities driven by technological advancements, demographic trends, and evolving healthcare needs. Innovations in molecular diagnostic technologies, such as the development of portable diagnostic devices and the integration of artificial intelligence (AI) in diagnostics, are opening new avenues for market growth. The increasing application of molecular diagnostics in various therapeutic areas, including oncology, infectious diseases, and genetic disorders, is expanding the market scope. Strategic partnerships, investments in R&D, and the introduction of cost-effective diagnostic solutions are essential for capitalizing on emerging opportunities and sustaining market leadership.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the molecular diagnostics market globally?
  • Which diagnostic technologies and applications are driving the adoption of molecular diagnostics in different healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the molecular diagnostics market?
  • Who are the key players contributing to the molecular diagnostics market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global molecular diagnostics market?

Competitive Intelligence and Business Strategy:

Leading players in the global molecular diagnostics market, including Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced diagnostic technologies, including next-generation sequencing and real-time PCR systems, catering to diverse diagnostic needs and clinical applications. Collaborations with healthcare providers, research institutions, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practices, and patient education fosters market growth and enhances diagnostic accuracy and outcomes.

Key Companies Profiled:

  • Becton, Dickinson and Company
  • Bio-Rad Laboratories In
  • Merck KgaA
  • Thermo Fisher Scientific Inc
  • Agilent Technologies, Inc.
  • F. Hoffman - La Roche Ltd.
  • Illumina, Inc.
  • Qiagen N.V.
  • Hologic Inc.
  • Siemens Healthineers AG
  • Seegene, Inc.
  • DiaSorin S.p.A
  • Grifols, S.A.
  • bioMerieux
  • QuidelOrtho Corporation
  • RapidBio

Molecular Diagnostics Market Research Segmentation

By Product Type:

  • Instruments
  • Reagent
  • Assay Kits
  • Consumables

By Disease Area:

  • Infectious Disease
  • Diabetes
  • Cardiology
  • Oncology
  • Nephrology
  • Autoimmune Disease
  • Dermatology
  • Wound Care
  • Others

By End-use:

  • Hospitals & Clinics
  • Diagnostics Laboratories
  • Academic and Research Institutes
  • Biopharmaceutical Companies

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Molecular Diagnostics Market Snapshot, 2024 - 2031
  • 1.2. Market Opportunity Assessment, 2024 - 2031, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Molecular Diagnostics Market: Value Chain
    • 2.3.1. List of Manufacturers
    • 2.3.2. List of Distributors
    • 2.3.3. Profitability Analysis
  • 2.4. Macro-Economic Factors
    • 2.4.1. Global Sectorial Outlook
    • 2.4.2. Global GDP Growth Outlook
    • 2.4.3. Global Parent Market Overview
  • 2.5. Forecast Factors - Relevance and Impact
  • 2.6. Covid-19 Impact Assessment
  • 2.7. Technology Advancement
  • 2.8. Disease Epidemiology
  • 2.9. Porter Five Force's Analysis
  • 2.10. Regulatory Scenario
  • 2.11. Product Adoption Analysis
  • 2.12. Parent Market Analysis

3. Price Trend Analysis, 2024 - 2031

  • 3.1. Key Highlights
  • 3.2. Key Factors Impacting Product Prices
  • 3.3. Prices by Product Type
  • 3.4. Regional Prices and Product Preferences

4. Global Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

  • 4.1. Key Highlights
    • 4.1.1. Market Volume (Units) Projections, by Product Type
    • 4.1.2. Market Size and Y-o-Y Growth
    • 4.1.3. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn ) Analysis and Forecast
    • 4.2.1. Historical Market Size Analysis, 2019-2023
    • 4.2.2. Current Market Size Forecast, 2024 - 2031
  • 4.3. Global Molecular Diagnostics Market Outlook: Product Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn ) and Volume (Units) Analysis by Product Type, 2019-2023
    • 4.3.3. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
      • 4.3.3.1. Instruments
        • 4.3.3.1.1. Polymerase Chain Reaction (PCR) Systems
        • 4.3.3.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
        • 4.3.3.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
        • 4.3.3.1.4. Microarrays
      • 4.3.3.2. Reagent
        • 4.3.3.2.1. Antibodies
        • 4.3.3.2.2. DNA Template
        • 4.3.3.2.3. DNA Polymerase
        • 4.3.3.2.4. Oligonucleotide Primers
        • 4.3.3.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
        • 4.3.3.2.6. Buffer
      • 4.3.3.3. Assay Kits
      • 4.3.3.4. Consumables
  • 4.4. Market Attractiveness Analysis: Product Type
  • 4.5. Global Molecular Diagnostics Market Outlook: Disease Area
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn ) Analysis By Disease Area, 2019-2023
    • 4.5.3. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
      • 4.5.3.1. Infectious Disease
      • 4.5.3.2. Diabetes
      • 4.5.3.3. Cardiology
      • 4.5.3.4. Oncology
      • 4.5.3.5. Nephrology
      • 4.5.3.6. Autoimmune Disease
      • 4.5.3.7. Dermatology
      • 4.5.3.8. Wound Care
      • 4.5.3.9. Others
  • 4.6. Market Attractiveness Analysis: Disease Area
  • 4.7. Global Molecular Diagnostics Market Outlook: End User
    • 4.7.1. Introduction / Key Findings
    • 4.7.2. Historical Market Size (US$ Bn ) Analysis by End User, 2019-2023
    • 4.7.3. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
      • 4.7.3.1. Hospitals & Clinics
      • 4.7.3.2. Diagnostics Laboratories
      • 4.7.3.3. Academic and Research Institutes
      • 4.7.3.4. Biopharmaceutical Companies
  • 4.8. Market Attractiveness Analysis: End User

5. Global Molecular Diagnostics Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn ) Analysis by Region, 2019-2023
  • 5.3. Current Market Size (US$ Bn ) Forecast by Region, 2024 - 2031
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
    • 6.2.1. by Country
    • 6.2.2. by Product Type
    • 6.2.3. By Disease Area
    • 6.2.4. by End User
  • 6.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
    • 6.4.1. Instruments
      • 6.4.1.1. Polymerase Chain Reaction (PCR) Systems
      • 6.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
      • 6.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
      • 6.4.1.4. Microarrays
    • 6.4.2. Reagent
      • 6.4.2.1. Antibodies
      • 6.4.2.2. DNA Template
      • 6.4.2.3. DNA Polymerase
      • 6.4.2.4. Oligonucleotide Primers
      • 6.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
      • 6.4.2.6. Buffer
    • 6.4.3. Assay Kits
    • 6.4.4. Consumables
  • 6.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
    • 6.5.1. Infectious Disease
    • 6.5.2. Diabetes
    • 6.5.3. Cardiology
    • 6.5.4. Oncology
    • 6.5.5. Nephrology
    • 6.5.6. Autoimmune Disease
    • 6.5.7. Dermatology
    • 6.5.8. Wound Care
    • 6.5.9. Others
  • 6.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
    • 6.6.1. Hospitals & Clinics
    • 6.6.2. Diagnostics Laboratories
    • 6.6.3. Academic and Research Institutes
    • 6.6.4. Biopharmaceutical Companies
  • 6.7. Market Attractiveness Analysis

7. Europe Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
    • 7.2.1. by Country
    • 7.2.2. by Product Type
    • 7.2.3. By Disease Area
    • 7.2.4. by End User
  • 7.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkiye
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
    • 7.4.1. Instruments
      • 7.4.1.1. Polymerase Chain Reaction (PCR) Systems
      • 7.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
      • 7.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
      • 7.4.1.4. Microarrays
    • 7.4.2. Reagent
      • 7.4.2.1. Antibodies
      • 7.4.2.2. DNA Template
      • 7.4.2.3. DNA Polymerase
      • 7.4.2.4. Oligonucleotide Primers
      • 7.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
      • 7.4.2.6. Buffer
    • 7.4.3. Assay Kits
    • 7.4.4. Consumables
  • 7.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
    • 7.5.1. Infectious Disease
    • 7.5.2. Diabetes
    • 7.5.3. Cardiology
    • 7.5.4. Oncology
    • 7.5.5. Nephrology
    • 7.5.6. Autoimmune Disease
    • 7.5.7. Dermatology
    • 7.5.8. Wound Care
    • 7.5.9. Others
  • 7.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
    • 7.6.1. Hospitals & Clinics
    • 7.6.2. Diagnostics Laboratories
    • 7.6.3. Academic and Research Institutes
    • 7.6.4. Biopharmaceutical Companies
  • 7.7. Market Attractiveness Analysis

8. East Asia Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
    • 8.2.1. by Country
    • 8.2.2. by Product Type
    • 8.2.3. By Disease Area
    • 8.2.4. by End User
  • 8.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
    • 8.4.1. Instruments
      • 8.4.1.1. Polymerase Chain Reaction (PCR) Systems
      • 8.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
      • 8.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
      • 8.4.1.4. Microarrays
    • 8.4.2. Reagent
      • 8.4.2.1. Antibodies
      • 8.4.2.2. DNA Template
      • 8.4.2.3. DNA Polymerase
      • 8.4.2.4. Oligonucleotide Primers
      • 8.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
      • 8.4.2.6. Buffer
    • 8.4.3. Assay Kits
    • 8.4.4. Consumables
  • 8.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
    • 8.5.1. Infectious Disease
    • 8.5.2. Diabetes
    • 8.5.3. Cardiology
    • 8.5.4. Oncology
    • 8.5.5. Nephrology
    • 8.5.6. Autoimmune Disease
    • 8.5.7. Dermatology
    • 8.5.8. Wound Care
    • 8.5.9. Others
  • 8.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
    • 8.6.1. Hospitals & Clinics
    • 8.6.2. Diagnostics Laboratories
    • 8.6.3. Academic and Research Institutes
    • 8.6.4. Biopharmaceutical Companies
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
    • 9.2.1. by Country
    • 9.2.2. by Product Type
    • 9.2.3. By Disease Area
    • 9.2.4. by End User
  • 9.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
  • 9.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
    • 9.4.1. Instruments
      • 9.4.1.1. Polymerase Chain Reaction (PCR) Systems
      • 9.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
      • 9.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
      • 9.4.1.4. Microarrays
    • 9.4.2. Reagent
      • 9.4.2.1. Antibodies
      • 9.4.2.2. DNA Template
      • 9.4.2.3. DNA Polymerase
      • 9.4.2.4. Oligonucleotide Primers
      • 9.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
      • 9.4.2.6. Buffer
    • 9.4.3. Assay Kits
    • 9.4.4. Consumables
  • 9.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
    • 9.5.1. Infectious Disease
    • 9.5.2. Diabetes
    • 9.5.3. Cardiology
    • 9.5.4. Oncology
    • 9.5.5. Nephrology
    • 9.5.6. Autoimmune Disease
    • 9.5.7. Dermatology
    • 9.5.8. Wound Care
    • 9.5.9. Others
  • 9.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
    • 9.6.1. Hospitals & Clinics
    • 9.6.2. Diagnostics Laboratories
    • 9.6.3. Academic and Research Institutes
    • 9.6.4. Biopharmaceutical Companies
  • 9.7. Market Attractiveness Analysis

10. Latin America Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
    • 10.2.1. by Country
    • 10.2.2. by Product Type
    • 10.2.3. By Disease Area
    • 10.2.4. by End User
  • 10.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
    • 10.4.1. Instruments
      • 10.4.1.1. Polymerase Chain Reaction (PCR) Systems
      • 10.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
      • 10.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
      • 10.4.1.4. Microarrays
    • 10.4.2. Reagent
      • 10.4.2.1. Antibodies
      • 10.4.2.2. DNA Template
      • 10.4.2.3. DNA Polymerase
      • 10.4.2.4. Oligonucleotide Primers
      • 10.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
      • 10.4.2.6. Buffer
    • 10.4.3. Assay Kits
    • 10.4.4. Consumables
  • 10.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
    • 10.5.1. Infectious Disease
    • 10.5.2. Diabetes
    • 10.5.3. Cardiology
    • 10.5.4. Oncology
    • 10.5.5. Nephrology
    • 10.5.6. Autoimmune Disease
    • 10.5.7. Dermatology
    • 10.5.8. Wound Care
    • 10.5.9. Others
  • 10.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
    • 10.6.1. Hospitals & Clinics
    • 10.6.2. Diagnostics Laboratories
    • 10.6.3. Academic and Research Institutes
    • 10.6.4. Biopharmaceutical Companies
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
    • 11.2.1. by Country
    • 11.2.2. by Product Type
    • 11.2.3. By Disease Area
    • 11.2.4. by End User
  • 11.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
    • 11.4.1. Instruments
      • 11.4.1.1. Polymerase Chain Reaction (PCR) Systems
      • 11.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
      • 11.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
      • 11.4.1.4. Microarrays
    • 11.4.2. Reagent
      • 11.4.2.1. Antibodies
      • 11.4.2.2. DNA Template
      • 11.4.2.3. DNA Polymerase
      • 11.4.2.4. Oligonucleotide Primers
      • 11.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
      • 11.4.2.6. Buffer
    • 11.4.3. Assay Kits
    • 11.4.4. Consumables
  • 11.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
    • 11.5.1. Infectious Disease
    • 11.5.2. Diabetes
    • 11.5.3. Cardiology
    • 11.5.4. Oncology
    • 11.5.5. Nephrology
    • 11.5.6. Autoimmune Disease
    • 11.5.7. Dermatology
    • 11.5.8. Wound Care
    • 11.5.9. Others
  • 11.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
    • 11.6.1. Hospitals & Clinics
    • 11.6.2. Diagnostics Laboratories
    • 11.6.3. Academic and Research Institutes
    • 11.6.4. Biopharmaceutical Companies
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping by Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Becton, Dickinson and Company
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Bio-Rad Laboratories Inc
      • 12.3.2.1. Overview
      • 12.3.2.2. Segments and Products
      • 12.3.2.3. Key Financials
      • 12.3.2.4. Market Developments
      • 12.3.2.5. Market Strategy
    • 12.3.3. Thermo Fisher Scientific Inc.
      • 12.3.3.1. Overview
      • 12.3.3.2. Segments and Products
      • 12.3.3.3. Key Financials
      • 12.3.3.4. Market Developments
      • 12.3.3.5. Market Strategy
    • 12.3.4. Merck KGaA
      • 12.3.4.1. Overview
      • 12.3.4.2. Segments and Products
      • 12.3.4.3. Key Financials
      • 12.3.4.4. Market Developments
      • 12.3.4.5. Market Strategy
    • 12.3.5. Agilent Technologies, Inc.
      • 12.3.5.1. Overview
      • 12.3.5.2. Segments and Products
      • 12.3.5.3. Key Financials
      • 12.3.5.4. Market Developments
      • 12.3.5.5. Market Strategy
    • 12.3.6. Hoffmann la roche
      • 12.3.6.1. Overview
      • 12.3.6.2. Segments and Products
      • 12.3.6.3. Key Financials
      • 12.3.6.4. Market Developments
      • 12.3.6.5. Market Strategy
    • 12.3.7. Qiagen N.V.
      • 12.3.7.1. Overview
      • 12.3.7.2. Segments and Products
      • 12.3.7.3. Key Financials
      • 12.3.7.4. Market Developments
      • 12.3.7.5. Market Strategy
    • 12.3.8. Illumina, Inc.
      • 12.3.8.1. Overview
      • 12.3.8.2. Segments and Products
      • 12.3.8.3. Key Financials
      • 12.3.8.4. Market Developments
      • 12.3.8.5. Market Strategy
    • 12.3.9. DiaSorin S.p.A
      • 12.3.9.1. Overview
      • 12.3.9.2. Segments and Products
      • 12.3.9.3. Key Financials
      • 12.3.9.4. Market Developments
      • 12.3.9.5. Market Strategy
    • 12.3.10. Hologic Inc.
      • 12.3.10.1. Overview
      • 12.3.10.2. Segments and Products
      • 12.3.10.3. Key Financials
      • 12.3.10.4. Market Developments
      • 12.3.10.5. Market Strategy
    • 12.3.11. Siemens Healthineers AG
      • 12.3.11.1. Overview
      • 12.3.11.2. Segments and Products
      • 12.3.11.3. Key Financials
      • 12.3.11.4. Market Developments
      • 12.3.11.5. Market Strategy
    • 12.3.12. Seegene, Inc.
      • 12.3.12.1. Overview
      • 12.3.12.2. Segments and Products
      • 12.3.12.3. Key Financials
      • 12.3.12.4. Market Developments
      • 12.3.12.5. Market Strategy
    • 12.3.13. Grifols, S.A.
      • 12.3.13.1. Overview
      • 12.3.13.2. Segments and Products
      • 12.3.13.3. Key Financials
      • 12.3.13.4. Market Developments
      • 12.3.13.5. Market Strategy
    • 12.3.14. bioMerieux
      • 12.3.14.1. Overview
      • 12.3.14.2. Segments and Products
      • 12.3.14.3. Key Financials
      • 12.3.14.4. Market Developments
      • 12.3.14.5. Market Strategy
    • 12.3.15. QuidelOrtho Corporation
      • 12.3.15.1. Overview
      • 12.3.15.2. Segments and Products
      • 12.3.15.3. Key Financials
      • 12.3.15.4. Market Developments
      • 12.3.15.5. Market Strategy
    • 12.3.16. RapidBio
      • 12.3.16.1. Overview
      • 12.3.16.2. Segments and Products
      • 12.3.16.3. Key Financials
      • 12.3.16.4. Market Developments
      • 12.3.16.5. Market Strategy
    • 12.3.17. Abbott Laboratories
      • 12.3.17.1. Overview
      • 12.3.17.2. Segments and Products
      • 12.3.17.3. Key Financials
      • 12.3.17.4. Market Developments
      • 12.3.17.5. Market Strategy
    • 12.3.18. Danaher Corporation
      • 12.3.18.1. Overview
      • 12.3.18.2. Segments and Products
      • 12.3.18.3. Key Financials
      • 12.3.18.4. Market Developments
      • 12.3.18.5. Market Strategy

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations